Who Owns Acumen Pharmaceuticals Stock?
NASDAQ: ABOSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 66.59%
- Held by insiders
- 6.79%
- Institutional holders
- 130
- Institutions 66.6%
- Insiders 6.8%
- Public and other 26.6%
Who owns Acumen Pharmaceuticals stock?
Institutional investors own about 66.6% of Acumen Pharmaceuticals's shares, spread across 130 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 6.79% of ABOS.
The largest institutional holders are RA Capital Management, L.P. (29.03%), Sands Capital Alternatives, LLC (5.14%) and Blackrock Inc. (3.44%). Together, the top 10 institutions control 54.7% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their ABOS positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ABOS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 20.99M | 29.03% | 0.0% |
| Sands Capital Alternatives, LLC | 3.72M | 5.14% | 0.0% |
| Blackrock Inc. | 2.49M | 3.44% | +1296.4% |
| Alyeska Investment Group, L.p. | 2.45M | 3.39% | 0.0% |
| Franklin Resources, Inc. | 2.31M | 3.19% | 0.0% |
| Adar1 Capital Management, LLC | 2.11M | 2.92% | -2.1% |
| Vanguard Capital Management LLC | 1.67M | 2.31% | +11.0% |
| Knollwood Investment Advisory, LLC | 1.63M | 2.25% | 0.0% |
| Geode Capital Management, LLC | 1.14M | 1.58% | +174.3% |
| Ikarian Capital, LLC | 1.05M | 1.46% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ABOS
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.12M | 1.55% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 1.05M | 1.45% |
| iShares Trust-iShares Russell 2000 ETF | 1.02M | 1.41% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 513.77K | 0.71% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 513.51K | 0.71% |
| iShares Trust-iShares Russell 2000 Value ETF | 425.50K | 0.59% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 229.68K | 0.32% |
| iShares Trust-iShares Micro-Cap ETF | 157.59K | 0.22% |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 115.09K | 0.16% |
| Dimensional ETF Trust-Dimensional U.S. Small Cap ETF | 100.01K | 0.14% |
Frequently asked questions
Who is the largest shareholder of Acumen Pharmaceuticals?
RA Capital Management, L.P. is the largest institutional shareholder of ABOS, owning 29.03% of shares outstanding (20.99M shares) as of its latest 13F filing.
What percentage of Acumen Pharmaceuticals is owned by institutions?
Institutions own about 66.6% of ABOS shares and 71.4% of the public float.
How much of Acumen Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 6.79% of ABOS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.